- Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL in the Phase III STARGLO study - - There is an urgent need ...

NEW YORK, June 26, 2020 /CNW/ -- MDC Partners Inc. (the "Company") (NASDAQ: MDCA) today announced that its Board of Directors has formed a special committee of independent directors to review the ...

New independent board members with experience in AI infrastructure and the evaluation of entrepreneurial ventures added to form a special committee Special committee to evaluate merits of ...

The evaluation committee considered evidence submitted by Takeda and a review of this submission by the external assessment group (EAG). See the committee papers for full details of the evidence.

“Today’s committee decision to recognize the potential of this Polivy combination as a first-line treatment option is important since four in 10 people with diffuse large B-cell lymphoma relapse or do ...

DUBLIN, Sept. 9, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted to ...

ABBOTT PARK, Ill. — A Food and Drug Administration advisory committee has voted to recommend that the FDA retain approval of an Abbott drug for high cholesterol in combination with a statin. The FDA’s ...

Please provide your email address to receive an email when new articles are posted on . The FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 13-7 for approval of the novel combination ...

There is "no therapeutic justification" for 14 fixed dose combination medications, including Nimesulide and Paracetamol dispersible tablets and Chlopheniramine Maleate and Codeine syrup, which the ...

ODAC voted 7–1 (one abstention) that capivasertib plus abiraterone and ADT shows a favorable benefit–risk profile for ...